Connor, Clark & Lunn Investment Management (CC&L)’s Aquestive Therapeutics AQST Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-47,817	Closed	-$124K	–	1423
2024 Q2	$124K	Sell	47,817 -171,582	-78%	-$573K	﹤0.01%	1299
2024 Q1	$935K	Sell	219,399 -42,193	-16%	-$140K	﹤0.01%	907
2023 Q4	$528K	Buy	261,592 +13,764	+6%	+$24.3K	﹤0.01%	1031
2023 Q3	$379K	Buy	247,828 +30,898	+14%	+$53.1K	﹤0.01%	1086
2023 Q2	$358K	Buy	+216,930	New	+$392K	﹤0.01%	1071
2022 Q2	–	Sell	-31,396	Closed	-$82K	–	1033
2022 Q1	$82K	Buy	31,396 +3,014	+11%	+$8.8K	﹤0.01%	984
2021 Q4	$110K	Buy	+28,382	New	+$142K	﹤0.01%	1028

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s AQST Position: Q3 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Aquestive Therapeutics (AQST) in Q3 2024, closing a stake of 47,817 shares — an estimated $124K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in AQST in Q4 2021 and held it in 7 quarters. The position peaked at $935K in Q1 2024. 117 funds tracked by Wall St. Rank hold AQST as of Q3 2024.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Aquestive Therapeutics position as of Q3 2024 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 47,817 Aquestive Therapeutics shares in Q3 2024, an estimated $124K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Aquestive Therapeutics in Q4 2021 and held it in 7 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Aquestive Therapeutics position peaked at $935K in Q1 2024.
117 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2024, filed 8 Nov 2024.